基蛋生物(603387.SH):擬參與投資設立南京創熠時節致遠一期
格隆匯9月24日丨基蛋生物(603387.SH)公佈,為優化投資結構,提升投資價值,公司擬參與投資設立南京創熠時節致遠一期創業投資合夥企業(有限合夥)(暫定名,以企業登記機關最終核准登記的名稱為準,“合夥企業”或“南京時節”),合夥企業認繳出資總額為2億元,公司作為有限合夥人計劃出資規模為人民幣4000萬元,佔比20%,根據投資業務的實際需要分二期繳付,各期出資為認繳出資額的比例分別為50%。
主要投資方向及投資目標:以醫療健康領域為核心,重點關注新藥研發、醫療器械及生物科技類公司。整體投向原則上不超出南京市級科技創新基金投向範疇。合夥企業的投資目標主要投資於初創、小微、成長等不同性質和發展階段的科技企業以及平台,重點投向處於天使、初創期的科技創新項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.